Lv1
10 积分 2024-04-22 加入
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
7天前
已完结
Current and Future Treatment Options in the Management of Stage III NSCLC
7天前
已完结
Pathways and targeting avenues of BRAF in non-small cell lung cancer
11天前
已完结
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
12天前
已完结
Outcomes and Management of Immune Checkpoint Inhibitor–Induced Hypothyroidism: A Retrospective Analysis
24天前
已完结
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
3个月前
已完结
Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate
5个月前
已完结
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
5个月前
已完结
Refining the treatment of NSCLC according to histological and molecular subtypes
5个月前
已完结
Rare molecular subtypes of lung cancer
5个月前
已完结
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis
皖公网安备34019202002308
